New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
05:12 EDTARWRArrowhead Research price target raised to $20 from $12 at Piper Jaffray
Piper Jaffray raised its price target for Arrowhead Research to $20 following the company's Q4 results and reiterates an Overweight rating on the stock. Piper sees blockbuster potential with ARC-520 for the treatment of Hepatitis-B Virus.
News For ARWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 15, 2014
09:57 EDTARWRLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:06 EDTARWRArrowhead pullback since ARC-520 data an overreaction, says Piper Jaffray
Subscribe for More Information
October 14, 2014
14:54 EDTARWRQVT Financial raises passive stake in Arrowhead to 7.62% from 5.29%
Subscribe for More Information
October 13, 2014
07:12 EDTARWROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
October 10, 2014
12:11 EDTARWROptions with increasing implied volatility
Subscribe for More Information
October 9, 2014
11:00 EDTARWROptions with increasing implied volatility
Options with increasing implied volatility: ARWR PBR EXXI PWE GST GLNG WTW AFSI ETE VALE
10:00 EDTARWROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:38 EDTARWRArrowhead price target lowered to $12 from $24 at Piper Jaffray
Subscribe for More Information
08:33 EDTARWRArrowhead issues letter to shareholders regarding ARC-520
Subscribe for More Information
06:18 EDTARWRArrowhead downgraded to Sector Perform from Outperform at RBC Capital
RBC Capital downgraded Arrowhead to Sector Perform citing low-end efficacy in the AASLD abstract. Price target lowered to $9.
05:50 EDTARWRStocks with implied volatility movement; ARWR TKMR
Stocks with implied volatility movement; Arrowhead (ARWR) 158, Tekmira (TKMR) 130 according to iVolatility.
October 8, 2014
16:26 EDTARWROn The Fly: Closing Wrap
Subscribe for More Information
13:12 EDTARWRArrowhead risk/reward favorable, says Deutsche Bank
Subscribe for More Information
11:48 EDTARWRArrowhead sell-off overdone, long-term view unchanged, says Jefferies
Subscribe for More Information
11:10 EDTARWROptions with increasing implied volatility
Subscribe for More Information
10:55 EDTARWRArrowhead ARC-520 treatment effect much lower than expected, TheStreet says
Subscribe for More Information
10:46 EDTARWRArrowhead plunges after HepB data abstract posted
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use